<p>(<b>A</b>). Mouse J774A.1 cells were treated with different concentrations of raltegravir (0, 5, 15, 25 or 50 µM) in the absence or presence of ritonavir (RITV, 25 µM) or thapsigargin (TG, 100 nM), a known ER stress inducer, for 4 h, and the nuclear proteins were isolated. Representative immunoblots from three independent experiments for CHOP, XBP-1, ATF-4 and lamin B are shown. Lamin B was used as the loading control for nuclear proteins. (<b>B</b>). Human THP-1-derived macrophages were treated with different concentrations of raltegravir (0, 5, 15, and 25 µM) in the absence or presence of lopinavir/ritonavir (LOPV/RITV, 25 µM) for 4 h. Representative immunoblots from three independent experiments for CHOP, XBP-1, ATF-4 and lamin B are ...
<p><b>A)</b> Representative immunoblots against CHOP, ATF-4 and Lamin B from nuclear extracts of mou...
<p>Mouse J774A.1 cells were treated with ritonavir (25 µM) with or without raltegravir (25 µM) for 2...
Background: Raltegravir (RAL) is the first integrase inhibitor approved for the treatment of HIV-1 ...
<p>Mouse J774A.1 cells were treated with HIV PIs (lopinavir/Ritonavir, 25 µM) with or without ralteg...
<p>Mouse J774A.1 cells were treated with lopinavir (LOPV, 25 µM) or ritonavir (RITV, 25 µM) with or ...
<p>Mouse J774A.1 cells were treated with ritonavir (RITV, 15 µM) with or without raltegravir (10, or...
HIV protease inhibitor (PI), the core component of highly active antiretroviral treatment (HAART) fo...
<p>(<b>A</b>) J774A.1 cells were loaded with Acetylated-LDL (50 µg/ml) and treated with 25 µM of LOP...
HIV protease inhibitor (PI), the core component of highly active antiretroviral treatment (HAART) fo...
HIV protease inhibitor (PI), the core component of highly active antiretroviral treatment (HAART) fo...
<div><p>Background</p><p>HIV protease inhibitor (PI), the core component of highly active antiretrov...
<p>Mouse primary peritoneal macrophages were isolated as described in “Methods” and cultured for 48 ...
<p>(<b>A</b>). Primary mouse peritoneal macrophages were loaded with Acetylated-LDL (50 µg/ml) and t...
<p>Mouse J774A.1 cells were treated with LOPV/RITV (15 µM) in the presence or absence of raltegravir...
Background HIV protease inhibitor (PI), the core component of highly active antiretroviral treatment...
<p><b>A)</b> Representative immunoblots against CHOP, ATF-4 and Lamin B from nuclear extracts of mou...
<p>Mouse J774A.1 cells were treated with ritonavir (25 µM) with or without raltegravir (25 µM) for 2...
Background: Raltegravir (RAL) is the first integrase inhibitor approved for the treatment of HIV-1 ...
<p>Mouse J774A.1 cells were treated with HIV PIs (lopinavir/Ritonavir, 25 µM) with or without ralteg...
<p>Mouse J774A.1 cells were treated with lopinavir (LOPV, 25 µM) or ritonavir (RITV, 25 µM) with or ...
<p>Mouse J774A.1 cells were treated with ritonavir (RITV, 15 µM) with or without raltegravir (10, or...
HIV protease inhibitor (PI), the core component of highly active antiretroviral treatment (HAART) fo...
<p>(<b>A</b>) J774A.1 cells were loaded with Acetylated-LDL (50 µg/ml) and treated with 25 µM of LOP...
HIV protease inhibitor (PI), the core component of highly active antiretroviral treatment (HAART) fo...
HIV protease inhibitor (PI), the core component of highly active antiretroviral treatment (HAART) fo...
<div><p>Background</p><p>HIV protease inhibitor (PI), the core component of highly active antiretrov...
<p>Mouse primary peritoneal macrophages were isolated as described in “Methods” and cultured for 48 ...
<p>(<b>A</b>). Primary mouse peritoneal macrophages were loaded with Acetylated-LDL (50 µg/ml) and t...
<p>Mouse J774A.1 cells were treated with LOPV/RITV (15 µM) in the presence or absence of raltegravir...
Background HIV protease inhibitor (PI), the core component of highly active antiretroviral treatment...
<p><b>A)</b> Representative immunoblots against CHOP, ATF-4 and Lamin B from nuclear extracts of mou...
<p>Mouse J774A.1 cells were treated with ritonavir (25 µM) with or without raltegravir (25 µM) for 2...
Background: Raltegravir (RAL) is the first integrase inhibitor approved for the treatment of HIV-1 ...